Continued High Prevalence and Adverse Clinical Impact of Human Immunodeficiency Virus–Associated Sensory Neuropathy in the Era of Combination Antiretroviral Therapy
Archives of NeurologyPublished 1 May 2010Open access
Ronald J. Ellis
Citations304
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Neuropathic pain and HIV-SN remain prevalent, causing substantial disability and reduced quality of life even with successful CART, and argue for redoubled efforts to determine HIV- SN pathogenesis and the development of symptomatic and neuroregenerative therapies.
Abstract
Neuropathic pain and HIV-SN remain prevalent, causing substantial disability and reduced quality of life even with successful CART. The clinical correlates of HIV-SN have changed with the evolution of treatment. These findings argue for redoubled efforts to determine HIV-SN pathogenesis and the development of symptomatic and neuroregenerative therapies.
Keywords
Immunology and MicrobiologyMedicine
The GerontologistAssessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living
18,541 Citations1969M. P. Lawton, Elaine Brody
Journal of Personality AssessmentComparison of Beck Depression Inventories-IA and-II in Psychiatric Outpatients
5,994 Citations1996Aaron T. Beck, Robert A. Steer +2 more
The amended (revised) Beck Depression Inventory (BDI-IA) and theBeck Depression Inventory-II (BDi-II) were self-administered to 140 psychiatric outpatients with various psychiatric disorders.
JAMAAntiretroviral Treatment of Adult HIV Infection
2,470 Citations2012Scott M. Hammer, Joseph J. Eron +13 more
New recommendations for HIV patient care include offering ART to all patients regardless of CD4 cell count, changes in therapeutic options, and modifications in the timing and choice of ART in the setting of opportunistic illnesses such as cryptococcal disease and tuberculosis.
SciencePositive Effects of Combined Antiretroviral Therapy on CD4 <sup>+</sup> T Cell Homeostasis and Function in Advanced HIV Disease
1,802 Citations1997Brigitte Autran, Guislaine Carcelain +7 more
The British Journal of PsychiatryCross-cultural Feasibility, Reliability and Sources of Variance of the Composite International Diagnostic Interview (CIDI)
839 Citations1991Hans‐Ulrich Wïttchen, L Robins +4 more
The CIDI was judged to be acceptable for most subjects and was appropriate for use in different kinds of settings, and no significant numbers of diagnostic disconcordances were found with lifetime, six-month, and four-week time frames.
Journal of the International Neuropsychological SocietyThe impact of HIV-associated neuropsychological impairment on everyday functioning
733 Citations2004Robert K. Heaton, Thomas D. Marcotte +8 more
Objective, laboratory based functional measures, such as those used here, may compliment NP testing in future studies directed at understanding the impact on life quality of central nervous system disorders and their treatments.
Quality of Life ResearchEvidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV)
548 Citations1997Albert W. Wu, Dennis A. Revicki +2 more
Research is needed to compare the MOS-HIV to other strategies for HRQoL assessment in early HIV disease and to suggest acceptable reliability and validity in women, injecting drug users and African–American and lower socioeconomic status patients.
Journal of NeuroVirologyThe Epidemiology of Human Immunodeficiency Virus-Associated Neurological Disease in the Era of Highly Active Antiretroviral Therapy
406 Citations2002Ned Sacktor
The incidence rates of HIV-associated neurological disease and central nervous system (CNS) opportunistic infections also are decreasing, and as patients develop increasing resistance mutations to antiretroviral drugs and with subsequent decline in CD4 cell counts, in the near future, the incidence of HIV’s neurological disease may begin to rise.
AIDSImpact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres
363 Citations1997Y Mouton, S. Alfandari +10 more
This study supports the extensive use of HAART in HIV-infected patients and shows a clear benefit to early HAART with a drop in hospitalization days, new AIDS cases, and deaths.
Annals of Internal MedicineQuality of Life in Persons with Human Immunodeficiency Virus Infection: Measurement by the Medical Outcomes Study Instrument
358 Citations1992Tom J. Wachtel, John D. Piette +4 more
The MOS survey is extremely sensitive to the effect of symptoms, which suggests that it might be useful as a quality-of-life indicator for AIDS clinical drug trials.
NeurologyPlasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy
305 Citations1999E.A. Childs, Robert H. Lyles +7 more
Levels of plasma HIV RNA and CD4 counts, determined before the initiation of antiretroviral therapy, were predictive of HIV-associated dementia and sensory neuropathy.
NeurologyPredominantly sensory neuropathy in patients with AIDS and AIDS‐related complex
297 Citations1988David R. Cornblath, Justin C. McArthur
Predominantly sensory neuropathy in HIV infection appears to be a distal axonal degeneration primarily involving sensory neurons, and the mechanism is unknown, but the neuropathy is associated with the late manifestations of HIV infection.
HIV MedicineFactors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study
198 Citations2003Éric Florence, Jens Lundgren +9 more
The prevalence and risk factors of poor CD4 count rise despite a good virological response on highly active antiretroviral treatment (HAART) are described.
AIDSIncidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea
196 Citations2000Richard D. Moore, Wai-Ming E. Wong +2 more
Based on the data, the risk of neuropathy is additive or even synergistic for ddI’s+ d4T’+“hydroxyurea compared with ddI or d4T alone, and the combination of ddI-+-“d44T also increases the riskof neuropathy but less than when hydroxyurea is included.
NeurologyHIV neuropathy natural history cohort study
175 Citations2006David M. Simpson, Douglas Kitch +13 more
In this cohort of advanced HIV infection–infected subjects, distal sensory polyneuropathy was common and relatively stable over 48 weeks, and previously established risk factors, including CD4 cell count, plasma HIV RNA, and use of dideoxynucleoside antiretrovirals were not predictive of the progression of DSP.
Clinical Infectious DiseasesModification of the Incidence of Drug-Associated Symmetrical Peripheral Neuropathy by Host and Disease Factors in the HIV Outpatient Study Cohort
146 Citations2004Kenneth Lichtenstein, Carl Armon +5 more
Delaying the initiation of therapy may select those individuals who will be more likely to develop SPN, and earlier initiation of HAART may decrease the risk of developing this common problem, as well as increase the therapeutic effects and decrease the toxic effects of the drugs.
Annals of NeurologySensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: Protease inhibitor–mediated neurotoxicity
139 Citations2006Jacqueline A. Pettersen, Gareth J. Jones +6 more
This work investigated the clinical features and associated pathogenic determinants of HIV‐SN in a neurological cohort of HIV-infected patients, together with a novel model ofAIDS‐associated sensory neuropathy.
Archives of NeurologyPeripheral Nerve Function in HIV Infection
136 Citations1999Michele Tagliati, Juliet Grinnell +2 more
Deterioration of values on nerve conduction studies, irrespective of the clinical diagnosis of DSP, was significantly correlated with low CD4 counts, aging, abnormal serum albumin and hemoglobin levels, and weight loss.
NeurologyAntiretroviral use and other risks for HIV-associated neuropathies in an international cohort
115 Citations2006Catherine L. Cherry, Richard L. Skolasky +10 more
Exposure to stavudine and didanosine was significantly associated with a heightened risk for symptomatic sensory neuropathy and reduced vibration thresholds and epidermal nerve fiber densities had the highest diagnostic efficiency of the laboratory indicators of neuropathy examined, but were relatively insensitive in isolation.
Annals of NeurologyHuman immunodeficiency virus protease inhibitors and risk for peripheral neuropathy
99 Citations2008Ronald J. Ellis, Jennifer Marquie‐Beck +11 more
Confirmation of peripheral nerve toxicity with PIs could substantially limit their long‐term use in highly active ARV therapy.
AIDSSeverity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels
94 Citations2002David M. Simpson, Anna‐Bettina Haidich +5 more
There is an association between plasma HIV-1 RNA levels and the severity of pain and QST results in HIV-associated DSP and further studies are needed to determine if aggressive use of antiretroviral drugs, including the use of dideoxynucleosides, may be of benefit to prevent or improve peripheral neuropathy.
Journal of Clinical VirologyNucleoside analogues and neuropathy in the era of HAART
89 Citations2003Catherine L. Cherry, Justin C. McArthur +2 more
The evidence for the neurotoxicity of HIV and HIV treatments, the effect of nucleoside reverse transcriptase inhibitors on mitochondria, and the likely associations between these are explored.
Journal of NeuroVirologyClinical validation of the NeuroScreen
73 Citations2005Ronald J. Ellis, Scott Evans +22 more
Predictive values suggest that the NeuroScreen will be useful for tracking trends in the prevalence of HIV-associated neurologic disease in large cohorts in the era of combination antiretroviral therapy, but may be less useful in evaluating individual patients.
The Journal of Infectious DiseasesHIV‐1 Virologic and Immunologic Progression and Initiation of Antiretroviral Therapy among HIV‐1–Infected Subjects in a Trial of the Efficacy of Recombinant Glycoprotein 120 Vaccine
72 Citations2005Peter B. Gilbert, Marta Ackers +8 more
The study results report the results that pertain to the effect of vaccination on the postinfection end points and it is concluded that the vaccine did not affect HIV-1 disease progression.
Current Opinion in NeurologyRecent advances in HIV neuropathy
70 Citations2006David R. Cornblath, Ahmet Höke
Animal models of the disease will allow researchers to ‘manipulate’ the system and it is hoped that these types of studies will translate to an improved understanding of the pathogenesis of HIV-associated neuropathies leading to better treatments.
AIDSIncreased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV-infected individuals
64 Citations2000Ronan Breen, Marc Lipman +1 more
AIDSHemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy
62 Citations2006Asha Kallianpur, Todd Hulgan +7 more
Iron-loading HFE mutations such as C282Y are associated with a decreased risk of PN during antiretroviral therapy, particularly in populations at risk of iron deficiency.
European Journal of NeurologyRisk modifiers for peripheral sensory neuropathy in HIV infection/AIDS
40 Citations2004Olatz López-Fernández, James T. Becker +2 more
At study entry, neuropathy was associated with acquired immunodeficiency syndrome (AIDS), nucleoside analogue reverse transcriptase inhibitors (NRTI) (i.e. ddC), and history of alcohol abuse, and after 1‐year follow‐up, the development of neuropathywas predicted by AIDS, age (older subjects), and NRTI use.
Current Infectious Disease ReportsControlling neuropathic pain in HIV
31 Citations2004Susama Verma, Lydia Estanislao +2 more
Treatment options for painful HIV neuropathy are reviewed, including experimental agents studied in recent and ongoing clinical trials.
AIDSPeripheral neuropathies associated with HIV and hepatitis C co-infection: a review
29 Citations2005Lydia Estanislao, Susan Morgello +1 more
There is a need for studies to further elucidate the mechanisms involved in co-infection with HIV and hepatitis C and whether there are additive or synergistic effects on the peripheral nerve by these two viruses.
Supplements to Clinical neurophysiologyChapter 22 Peripheral neuropathies in human immunodeficiency virus infection
23 Citations2004Ahmet Höke, David R. Cornblath
This chapter discusses the various peripheral neuropathies in human immunodeficiency virus (HIV) infection, including HIV-associated sensory neuro paths, inflammatory polyneuropathies, mononeuritis multiplex, autonomic neuropathy, neuropathy in diffuse infiltrative lymphomatosis syndrome, and neuro paths caused by opportunistic infections.
HIV MedicineImpact of long‐term treatment with neurotoxic dideoxynucleoside antiretrovirals: implications for clinical care in resource‐limited settings
13 Citations2008CF Hung, SA Gibson +5 more
A minority of HIV‐infected patients taking an antiretroviral regimen containing dideoxynucleosides such as stavudine (d4T) and didanosine (DDI) experiences dose‐limiting neuropathic pain and paraesthesias, usually within weeks of starting these drugs.
AIDS Research and Human RetrovirusesA Report on the Effect of Commencing Enfuvirtide on Peripheral Neuropathy
10 Citations2008Catherine L. Cherry, Alison Duncan +3 more
No clear evidence of neurotoxicity from enfuvirtide in this population of patients who would have been particularly vulnerable to a neurotoxin, with advanced HIV disease and a high rate of baseline neurological abnormalities is observed.